Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5930
    -0.0005 (-0.08%)
     

  • NZD/EUR

    0.5543
    +0.0002 (+0.04%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.66
    -0.70 (-0.84%)
     

  • GOLD

    2,338.20
    -3.90 (-0.17%)
     

  • NASDAQ

    17,480.71
    +9.24 (+0.05%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,387.89
    -115.80 (-0.30%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • NZD/JPY

    91.8880
    +0.1220 (+0.13%)
     

Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference

Xenon Pharmaceuticals Inc.
·1-min read
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in virtual one-on-one investor meetings and a fireside chat presentation at the 13th Annual Wedbush PacGrow (Virtual) Healthcare Conference.

Fireside Chat Details:

 

 

 

Date:

Wednesday, August 10, 2022

 

 

Time:

2:55-3:25 pm ET

 

 

Presenters:

Ian Mortimer, President and CEO

 

Sherry Aulin, CFO

A webcast of the fireside chat will be available on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.

ADVERTISEMENT

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com